ARHGAP16P

Across TCGA pan-cancer cohorts, ARHGAP16P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated ARHGAP16P data layer.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ARHGAP16P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP16P expression acts as an unfavorable survival marker, although some lineages such as BLCA and HNSC show a favorable association.

SKCM, LIHC, and ESCA are the cancer types where ARHGAP16P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Tertile	III,IV	0.058	0.648	.001	54	view →
LIHC	OS	Tertile	All	0.051	0.783	<.001	54	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
LUAD	OS	Tertile	III,IV	0.223	0.677	.006	27	view →
LUSC	OS	Tertile	III,IV	0.258	0.670	.023	18	view →
BLCA	DFS	Tertile	All	1.000	0.308	.047	12	view →
HNSC	DFS	Tertile	III,IV	0.506	0.285	.028	6	view →
BRCA	DFS	Median	III,IV	0.920	0.840	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARHGAP16P–SKCM (DFS)

Open the SKCM breakdown →